Nxera Pharma Co Ltd (SOLTF)
8.052
0.00 (0.00%)
USD |
OTCM |
Nov 14, 16:00
Nxera Pharma Enterprise Value: 818.86M for Nov. 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 14, 2024 | 818.86M |
| November 13, 2024 | 818.86M |
| November 12, 2024 | 818.86M |
| November 11, 2024 | 818.86M |
| November 08, 2024 | 780.93M |
| November 07, 2024 | 791.71M |
| November 06, 2024 | 791.71M |
| November 05, 2024 | 791.71M |
| November 04, 2024 | 791.71M |
| November 01, 2024 | 746.76M |
| October 31, 2024 | 746.76M |
| October 30, 2024 | 746.76M |
| October 29, 2024 | 731.48M |
| October 28, 2024 | 731.48M |
| October 25, 2024 | 781.83M |
| October 24, 2024 | 781.83M |
| October 23, 2024 | 781.83M |
| October 22, 2024 | 781.83M |
| October 21, 2024 | 736.16M |
| October 18, 2024 | 736.16M |
| October 17, 2024 | 736.16M |
| October 16, 2024 | 905.89M |
| October 15, 2024 | 905.89M |
| October 14, 2024 | 905.89M |
| October 11, 2024 | 905.89M |
| Date | Value |
|---|---|
| October 10, 2024 | 905.89M |
| October 09, 2024 | 905.89M |
| October 08, 2024 | 905.89M |
| October 07, 2024 | 905.89M |
| October 04, 2024 | 905.89M |
| October 03, 2024 | 905.89M |
| October 02, 2024 | 905.89M |
| October 01, 2024 | 905.89M |
| September 30, 2024 | 917.58M |
| September 27, 2024 | 917.58M |
| September 26, 2024 | 917.58M |
| September 25, 2024 | 917.58M |
| September 24, 2024 | 917.58M |
| September 23, 2024 | 917.58M |
| September 20, 2024 | 917.58M |
| September 19, 2024 | 917.58M |
| September 18, 2024 | 917.58M |
| September 17, 2024 | 833.97M |
| September 16, 2024 | 833.97M |
| September 13, 2024 | 833.97M |
| September 12, 2024 | 833.97M |
| September 11, 2024 | 833.97M |
| September 10, 2024 | 833.97M |
| September 09, 2024 | 833.97M |
| September 06, 2024 | 833.97M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
429.47M
Minimum
May 12 2022
1.579B
Maximum
May 25 2023
974.18M
Average
973.78M
Median
Jul 21 2020
Enterprise Value Benchmarks
| Takeda Pharmaceutical Co Ltd | 72.05B |
| PeptiDream Inc | 2.175B |
| Healios KK | 117.61M |
| AnGes Inc | 86.92M |
| SanBio Co Ltd | 247.52M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 8.079M |
| Revenue (Quarterly) | 62.36M |
| Total Expenses (Quarterly) | 56.92M |
| EPS Diluted (Quarterly) | 0.0906 |
| Gross Profit Margin (Quarterly) | 78.44% |
| Profit Margin (Quarterly) | 12.95% |
| Earnings Yield | -3.39% |
| Normalized Earnings Yield | -3.387 |